Anti-galactose-alpha-1,3-galactose immunoglobulin E (Anti-alpha-Gal IgE)

Anti-galactose-alpha-1,3-galactose (alpha-gal) IgE antibodies are specific immunoglobulins that recognize a carbohydrate epitope found on the glycoproteins and glycolipids of non-primate mammals. In humans, the production of these antibodies is primarily induced by the bite of certain tick species, such as Amblyomma americanum (the Lone Star tick), which introduces the alpha-gal antigen into the host. These antibodies are the causative agents of Alpha-gal syndrome (AGS), a unique allergy characterized by delayed hypersensitivity reactions occurring several hours after the consumption of mammalian meat like beef, pork, or lamb. Beyond dietary triggers, anti-alpha-Gal IgE is clinically significant in pharmacology because it can cause immediate, severe anaphylactic reactions to drugs containing the alpha-gal epitope, most notably the EGFR-inhibitor Cetuximab. Diagnosis is typically confirmed through serum testing for alpha-gal-specific IgE, and management involves strict avoidance of mammalian-derived products and, in some severe cases, the use of anti-IgE therapies to reduce sensitivity.

Other names

Anti-Gal IgEAlpha-gal IgEGalactose-alpha-1,3-galactose-specific IgEAnti-alpha-galactose IgE

Therapeutic strategies targeting these antibodies involve the use of anti-IgE monoclonal antibodies, such as Omalizumab, which bind to the Fc region of free IgE to prevent its interaction with high-affinity IgE receptors (FcεRI) on mast cells and basophils. In the context of adverse drug reactions, the mechanism involves the drug (e.g., Cetuximab) acting as an antigen where its alpha-gal epitopes cross-link pre-existing anti-alpha-Gal IgE on effector cells, triggering the release of inflammatory mediators.